Rockley Photonics Reports Second Quarter of Fiscal 2022 Financial Results
Signs Supply Agreement and Receives First Commercial Purchase Order from Top-Tier Medtech Company for Bioptx™ Baseline Band, Targets Fourth Quarter to Begin Shipping
Signs First Contract Research Organization Partnership to Develop and Evaluate Rockley’s Bioptx™ Biomarker Sensing Platform for Use in Clinical Trials
Bolsters Board of Directors and Establishes Scientific Advisory Board
OXFORD, England & PASADENA, Calif.–(BUSINESS WIRE)–$RKLY #earnings–Rockley Photonics Holdings Limited (NYSE: RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced its financial results for the second quarter ended June 30, 2022.
“I am proud of the progress we made in the second quarter. As we ramp towards commercial production, we have reached many of the milestones that we’ve been working towards and expect to reach many more in the coming months,” said Dr. Andrew Rickman, chairman and chief executive officer of Rockley. “I’m pleased with the progress that the team has made over the last year with our products and our customers. In August alone, we signed a supply agreement and received our first commercial purchase order, we also received the first production devices from our manufacturing partner, and we expanded our medtech market opportunity by adding contract research organizations as an additional market for our solutions. These announcements showcase many significant achievements for Rockley. I am looking forward to what is ahead of us as I believe that we are close to achieving our goal of having our biosensing solutions available to our customers in volume.”
“There are many value creation opportunities ahead for Rockley and I am committed to driving the financial strategy that supports them,” said Chad Becker, interim chief financial officer of Rockley. “In my first few weeks as interim CFO, I have focused on ensuring more efficient use of cash and adjusting our operating model as we advance toward the commercialization of our technology in consumer wearables and medtech products. We are committed to reducing our operating costs and conserving cash and have built a framework to support that while enabling a rapid move to commercial production.”
Business Highlights:
- Signed Supply Agreement and Received First Commercial Purchase Order – Following the delivery of the initial production devices of its Bioptx Baseline Band, the Company received its first commercial purchase order from a top 10, global medtech company. Rockley expects to ship the bands to the customer in the fourth quarter 2022, with volume production ramping in 2023.
- Signed Partnership with Contract Research Organization (CRO), Opening a New Market for Bioptx™ – A top 10 CRO which provides full-service clinical development services to biopharmaceutical customers signed a partnership agreement with Rockley to develop and evaluate its Bioptx biosensing wristband, cloud services, and other elements of its biomarker sensing platform, potentially integrating the health monitoring solutions into the CRO’s clinical research studies.
- Named Renowned Healthcare Leader Richard Kuntz, M.D., M.Sc. to Board of Directors – World-class industry, clinical and research leader Dr. Kuntz joins Rockley’s board of directors, bringing a broad background in multiple areas of healthcare innovation. He served as Medtronic’s global chief medical and scientific officer and led its leading neuromodulation business. He founded and served as chief scientific officer of the Harvard Clinical Research Institute. He served as an interventional cardiologist at the Brigham and Women’s Hospital and on the faculty of Harvard Medical School.
- Established Scientific Advisory Board (SAB) of Prominent Scientists and Medical Experts – Rockley has assembled experts in therapies for diseases in the areas of diabetes and cardiology, as well as human hydration and fundamental spectroscopy to further the Company’s ongoing efforts to revolutionize wearable biosensing technology. The SAB members will advise Rockley on its unique biosensing platform and provide input and guidance for Rockley’s efforts to realize the full potential of its biosensing platform for the consumer and medtech markets. The newly formed SAB will support Rockley’s mission of empowering people to make better-informed decisions about their health and well-being.
- Joined Russell 3000® Index – The Company announced that it joined the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective June 27, 2022. The inclusion in the index is expected to enhance the Company’s visibility within the broader market and raise its profile in the wearables market.
- Entered Evaluation Phase of VitalSpex™ Pro Technology by Leading Consumer Wearables Customer – During the quarter, the Company announced that one of its tier-1 consumer wearables customers has begun an evaluation program using Rockley’s photonics-based sensing technology. The tier-1 customer adds to Rockley’s growing list of global consumer electronics manufacturers to receive shipments of Rockley’s VitalSpex Pro technology, which is expected to enable the non-invasive measurement of alcohol, glucose, and lactate from a wrist-worn device.
Guidance:
- Revised 2022 Revenue Guidance – The Company expects to generate core product revenue of $5 – $10 million. While opportunities to monetize its datacom platform remain, Rockley has removed all revenue from datacom platform monetization in its revised guidance for 2022. Expenses related to the datacom asset have been eliminated, and the impact of datacom and other expense reductions is expected to be cash flow neutral.
- 2023 Revenue Guidance – Previous information provided for 2023 is not reflective of management’s current views of 2023 as the Company continues to evolve its business and financial model. The Company intends to provide its 2023 revenue guidance in the future.
Second Quarter of Fiscal Year 2022 Financial Highlights:
|
(in millions except per share) |
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
|
June 30, 2022 |
|
March 31, 2022 |
|
June 30, 2021 |
|
June 30, 2022 |
|
June 30, 2021 |
||||||||||
|
Revenue |
$ |
1.5 |
|
|
$ |
1.0 |
|
|
$ |
2.2 |
|
|
$ |
2.5 |
|
|
$ |
4.0 |
|
|
Gross profit |
$ |
(0.8 |
) |
|
$ |
(2.4 |
) |
|
$ |
(2.4 |
) |
|
$ |
(3.2 |
) |
|
$ |
(4.3 |
) |
|
SG&A expense |
$ |
21.2 |
|
|
$ |
10.9 |
|
|
$ |
6.7 |
|
|
$ |
32.1 |
|
|
$ |
14.0 |
|
|
R&D expense |
$ |
26.3 |
|
|
$ |
24.8 |
|
|
$ |
17.6 |
|
|
$ |
51.1 |
|
|
$ |
33.5 |
|
|
Net loss |
$ |
(121.8 |
) |
|
$ |
(41.8 |
) |
|
$ |
(30.6 |
) |
|
$ |
(163.6 |
) |
|
$ |
(95.3 |
) |
|
Net loss per share |
$ |
(0.94 |
) |
|
$ |
(0.33 |
) |
|
$ |
(0.36 |
) |
|
$ |
(1.27 |
) |
|
$ |
(1.13 |
) |
|
Cash, cash equivalents, and investments at period end |
$ |
46.6 |
|
|
$ |
36.4 |
|
|
$ |
35.4 |
|
|
$ |
46.6 |
|
|
$ |
35.4 |
|
|
Cash used in operations |
$ |
(41.2 |
) |
|
$ |
(38.8 |
) |
|
$ |
(29.6 |
) |
|
$ |
(80.0 |
) |
|
$ |
(54.5 |
) |
Non-GAAP Financial Highlights:
|
SG&A expense |
$ |
9.0 |
|
|
$ |
9.5 |
|
|
$ |
5.8 |
|
|
$ |
18.6 |
|
|
$ |
11.3 |
|
|
R&D expense |
$ |
23.1 |
|
|
$ |
21.2 |
|
|
$ |
15.7 |
|
|
$ |
44.3 |
|
|
$ |
30.1 |
|
|
Net loss |
$ |
(106.3 |
) |
|
$ |
(36.2 |
) |
|
$ |
(27.4 |
) |
|
$ |
(142.6 |
) |
|
$ |
(88.6 |
) |
|
Net loss per share |
$ |
(0.82 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.33 |
) |
|
$ |
(1.11 |
) |
|
$ |
(1.05 |
) |
|
Adjusted EBITDA |
$ |
(36.3 |
) |
|
$ |
(34.0 |
) |
|
$ |
(23.4 |
) |
|
$ |
(70.3 |
) |
|
$ |
(44.8 |
) |
A reconciliation of GAAP financial measures to non-GAAP financial measures is included in the financial statement tables included in this press release. For more information regarding the non-GAAP financial measures discussed in this press release, please see “Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Conference Call Information
Rockley will host a conference call and webcast to discuss the second quarter results at 5:00 p.m. Eastern Time today, August 11, 2022. The live audio webcast along with accompanying presentation materials will be accessible on the Company’s Investor Relations website at investors.rockleyphotonics.com.
The U.S. dial-in for the call is 866-682-6100 or +1 404-267-0373 for international callers. Please reference access code 13731648. A replay of the conference call will be available until September 10, 2022, at 11:59 p.m. Eastern Time, while an archived version of the webcast will be available on Rockley’s Investor Relations website for one year. The U.S. dial-in for the conference call replay is 877-660-6853 or +1 201-612-7415. The replay access code is 13731648.
Disclosure Information
In compliance with disclosure obligations under Regulation FD, Rockley announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls and webcasts, as well as the investor relations website.
About Rockley
A global leader in photonics-based health monitoring and communications solutions, Rockley is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Rockley’s future expectations, beliefs, plans, objectives, and assumptions regarding future events or performance. The words “anticipate,” “believe,” “continue,” “could,” “develop,” “enable,” “estimate,” “eventual,” “expect,” “future,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,” “possible,” “position,” “potential,” “predict,” “project,” “revolutionize,” “seem,” “should,” “trend,” “will,” “would” and other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) the expectation that Rockley will reach many milestones in the coming months; (b) the timing for achieving the goal of having Rockley’s biosensing solutions available to its customers in volume; (c) the value creation opportunities ahead for Rockley; (d) Rockley’s commitment to reducing its operating costs and conserving cash; (e) the expected timing for shipping Bioptx Baseline Band to customers and timing of volume production; (f) anticipated benefits and features of Rockley’s products and partnership agreements; (g) the anticipated benefits of being added to the Russell 3000® Index; and (h) anticipated financial results, including expected revenue for 2022.
Forward-looking statements are subject to several risks and uncertainties (many of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) the Company’s ability to achieve commercial production of its products and technology, including in a timely and cost-effective manner; (ii) the Company’s ability to achieve customer design wins, convert memoranda of understanding and development contracts into production contracts, and achieve customer acceptance of its products and technology; (iii) risks related to purchase orders, including the lack of long-term purchase commitments, the cancellation, reduction, delay, or other changes in customer purchase orders, and if and to the extent customers seek to enter into licensing arrangements in lieu of purchases; (iv) the Company’s history of losses and need for additional capital and its ability to access additional financing to support its operations and execute on its business plan, as well as the risks associated with any future financings; (v) legal and regulatory risks, including those related to its products and technology and any threatened or actual litigation; (vi) risks associated with its fabless manufacturing model and dependency on third-party suppliers; (vii) the Company’s reliance on a few significant customers for a majority of its revenue and its ability to expand and diversify its customer base; (viii) the Company’s financial performance; (ix) the impacts of COVID-19 on the Company, its customers and suppliers, its target markets, and the economy; (x) the Company’s ability to successfully manage growth and its operations as a public company; (xi) fluctuations in the Company’s stock price and the Company’s ability to maintain the listing of its ordinary shares on the NYSE; (xii) the Company’s ability to anticipate and respond to industry trends and customer requirements; (xiii) changes in the Company’s current and future target markets; (xiv) intellectual property risks; (xv) the Company’s ability to compete successfully; (xvi) market opportunity and market demand for, and acceptance of, the Company’s products and technology, as well as the customer products into which the Company’s products and technology are incorporated; (xvii) risks related to international operations; (xviii) risks related to cybersecurity, privacy, and infrastructure; (xix) risks related to financial and accounting matters; (xx) general economic, financial, legal, political, and business conditions and changes in domestic and foreign markets; (xxi) risks related to the Company’s debt arrangements, restrictions on the Company’s operations contained in those debt arrangements and compliance with the terms thereof; (xxii) changes adversely affecting the businesses or markets in which the Company is engaged; and (xxiii) risks related to the Company’s backlog, including the risk that backlog may not translate into future revenue, as well as other factors described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended 2021, and in other documents the Company files with the Securities and Exchange Commission in the future. The forward-looking statements contained in this press release are based on various assumptions, whether or not identified in this press release, and on the Company’s current expectations, beliefs, and assumptions and are not predictions of actual performance. If any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may differ materially from those discussed in or implied by these forward-looking statements. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements speak only as of the date hereof and the Company does not intend to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by law.
Second Quarter 2022 Financial Results
|
ROCKLEY PHOTONICS HOLDINGS LIMITED |
|||||||||||||||||||
|
Condensed Consolidated Statements of Operations |
|||||||||||||||||||
|
(Unaudited and in thousands, except share and per share amounts) |
|||||||||||||||||||
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
|
June 30, |
|
March 31, |
|
June 30, |
|
June 30, |
|
June 30, |
||||||||||
|
Revenue |
$ |
1,505 |
|
|
$ |
962 |
|
|
$ |
2,195 |
|
|
$ |
2,467 |
|
|
$ |
3,966 |
|
|
Cost of revenue |
|
2,292 |
|
|
|
3,395 |
|
|
|
4,549 |
|
|
|
5,687 |
|
|
|
8,283 |
|
|
Gross profit |
|
(787 |
) |
|
|
(2,433 |
) |
|
|
(2,354 |
) |
|
|
(3,220 |
) |
|
|
(4,317 |
) |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||||
|
Selling, general, and administrative expenses |
|
21,166 |
|
|
|
10,938 |
|
|
|
6,715 |
|
|
|
32,104 |
|
|
|
14,020 |
|
|
Research and development expenses |
|
26,299 |
|
|
|
24,802 |
|
|
|
17,551 |
|
|
|
51,101 |
|
|
|
33,531 |
|
|
Total operating expenses |
|
47,465 |
|
|
|
35,740 |
|
|
|
24,266 |
|
|
|
83,205 |
|
|
|
47,551 |
|
|
Loss from operations |
|
(48,252 |
) |
|
|
(38,173 |
) |
|
|
(26,620 |
) |
|
|
(86,425 |
) |
|
|
(51,868 |
) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
||||||||||
|
Other expense |
|
(155 |
) |
|
|
(14 |
) |
|
|
2,860 |
|
|
|
(169 |
) |
|
|
2,860 |
|
|
Interest expense, net |
|
(4,514 |
) |
|
|
(2,653 |
) |
|
|
(179 |
) |
|
|
(7,167 |
) |
|
|
(326 |
) |
|
Gain (loss) on equity method investment |
|
(169 |
) |
|
|
207 |
|
|
|
(597 |
) |
|
|
38 |
|
|
|
(760 |
) |
|
Change in fair value of debt instruments |
|
(47,579 |
) |
|
|
— |
|
|
|
(6,008 |
) |
|
|
(47,579 |
) |
|
|
(45,661 |
) |
|
Change in fair value of warrant liabilities |
|
(18,219 |
) |
|
|
211 |
|
|
|
— |
|
|
|
(18,008 |
) |
|
|
— |
|
|
(Loss) gain on foreign currency |
|
(3,417 |
) |
|
|
(1,228 |
) |
|
|
97 |
|
|
|
(4,645 |
) |
|
|
631 |
|
|
Total other income (expense) |
|
(74,053 |
) |
|
|
(3,477 |
) |
|
|
(3,827 |
) |
|
|
(77,530 |
) |
|
|
(43,256 |
) |
|
Loss before income taxes |
|
(122,305 |
) |
|
|
(41,650 |
) |
|
|
(30,447 |
) |
|
|
(163,955 |
) |
|
|
(95,124 |
) |
|
Provision for income tax (benefit) |
|
(468 |
) |
|
|
131 |
|
|
|
110 |
|
|
|
(337 |
) |
|
|
210 |
|
|
Net loss |
$ |
(121,837 |
) |
|
$ |
(41,781 |
) |
|
$ |
(30,557 |
) |
|
$ |
(163,618 |
) |
|
$ |
(95,334 |
) |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
||||||||||
|
Basic and diluted |
$ |
(0.94 |
) |
|
$ |
(0.33 |
) |
|
$ |
(0.36 |
) |
|
$ |
(1.27 |
) |
|
$ |
(1.13 |
) |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
||||||||||
|
Basic and diluted |
|
129,341,861 |
|
|
|
128,443,050 |
|
|
|
84,247,703 |
|
|
|
128,894,938 |
|
|
|
84,066,648 |
|
|
ROCKLEY PHOTONICS HOLDINGS LIMITED |
|||||||
|
Condensed Consolidated Balance Sheets |
|||||||
|
(Unaudited and in thousands, except share amounts and par value) |
|||||||
|
|
June 30, |
|
December 31, |
||||
|
Assets |
|
|
|
||||
|
Current assets |
|
|
|
||||
|
Cash and cash equivalents |
$ |
38,772 |
|
|
$ |
36,786 |
|
|
Short-term investments |
|
7,826 |
|
|
|
26,965 |
|
|
Accounts receivable, net of allowance of $0 and $302 as of June 30, 2022 and December 31, 2021, respectively |
|
1,466 |
|
|
|
1,359 |
|
|
Other receivables, net of allowance of $0 and $141 as of June 30, 2022 and December 31, 2021, respectively |
|
48,127 |
|
|
|
47,462 |
|
|
Prepaid expenses and other current assets |
|
6,259 |
|
|
|
6,802 |
|
|
Total current assets |
|
102,450 |
|
|
|
119,374 |
|
|
Long-term investments |
|
— |
|
|
|
17,659 |
|
|
Property and equipment, net |
|
10,161 |
|
|
|
10,187 |
|
|
Equity method investment |
|
5,060 |
|
|
|
4,879 |
|
|
Intangible assets, net |
|
3,048 |
|
|
|
3,048 |
|
|
Other non-current assets |
|
8,191 |
|
|
|
7,683 |
|
|
Total assets |
$ |
128,910 |
|
|
$ |
162,830 |
|
|
|
|
|
|
||||
|
Liabilities and Shareholders’ Equity (Deficit) |
|
|
|
||||
|
Current liabilities |
|
|
|
||||
|
Trade payables |
$ |
8,730 |
|
|
$ |
6,882 |
|
|
Accrued expenses |
|
15,730 |
|
|
|
17,360 |
|
|
Debt, current portion |
|
— |
|
|
|
26,312 |
|
|
Other current liabilities |
|
1,577 |
|
|
|
1,238 |
|
|
Total current liabilities |
|
26,037 |
|
|
|
51,792 |
|
|
Long-term debt, net of current portion |
|
97,561 |
|
|
|
— |
|
|
Warrant liabilities |
|
52,189 |
|
|
|
3,477 |
|
|
Other long-term liabilities |
|
3,588 |
|
|
|
3,743 |
|
|
Total liabilities |
|
179,375 |
|
|
|
59,012 |
|
|
|
|
|
|
||||
|
Shareholders’ equity (deficit) |
|
|
|
||||
|
Ordinary shares, $0.000004 par value; 12,443,961,038 and 12,417,500,000 authorized as of June 30, 2022 and December 31, 2021, respectively; 129,917,925 and 127,860,639 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively |
|
— |
|
|
|
— |
|
|
Additional paid-in-capital |
|
514,225 |
|
|
|
504,714 |
|
|
Accumulated other comprehensive loss |
|
(176 |
) |
|
|
— |
|
|
Accumulated deficit |
|
(564,514 |
) |
|
|
(400,896 |
) |
|
Total shareholders’ equity (deficit) |
|
(50,465 |
) |
|
|
103,818 |
|
|
Total liabilities and shareholders’ equity (deficit) |
$ |
128,910 |
|
|
$ |
162,830 |
|
|
ROCKLEY PHOTONICS HOLDINGS LIMITED |
||||||||||||||||||||
|
Condensed Consolidated Statements of Cash Flows |
||||||||||||||||||||
|
(Unaudited and in thousands) |
||||||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
|
|
June 30, |
|
March 31, |
|
June 30, |
|
June 30, |
|
June 30, |
||||||||||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Net loss |
|
$ |
(121,837 |
) |
|
$ |
(41,781 |
) |
|
$ |
(30,557 |
) |
|
$ |
(163,618 |
) |
|
$ |
(95,334 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Depreciation and amortization |
|
|
1,581 |
|
|
|
1,504 |
|
|
|
1,069 |
|
|
|
3,085 |
|
|
|
1,999 |
|
|
(Reversal) bad debt expense |
|
|
— |
|
|
|
(141 |
) |
|
|
— |
|
|
|
(141 |
) |
|
|
377 |
|
|
Accretion of marketable securities to redemption value |
|
|
(35 |
) |
|
|
(74 |
) |
|
|
— |
|
|
|
(109 |
) |
|
|
— |
|
|
Net realized loss on sale of marketable securities |
|
|
(155 |
) |
|
|
(13 |
) |
|
|
— |
|
|
|
(168 |
) |
|
|
— |
|
|
Stock-based compensation |
|
|
3,948 |
|
|
|
4,029 |
|
|
|
1,976 |
|
|
|
7,977 |
|
|
|
3,701 |
|
|
Change in equity-method investment |
|
|
153 |
|
|
|
(334 |
) |
|
|
604 |
|
|
|
(181 |
) |
|
|
491 |
|
|
Change in fair value of debt instrument |
|
|
47,579 |
|
|
|
— |
|
|
|
6,008 |
|
|
|
47,579 |
|
|
|
45,661 |
|
|
Change in fair value of warrant liabilities |
|
|
18,219 |
|
|
|
(211 |
) |
|
|
— |
|
|
|
18,008 |
|
|
|
— |
|
|
Forgiveness of Paycheck Protection Program loan |
|
|
— |
|
|
|
— |
|
|
|
(2,860 |
) |
|
|
— |
|
|
|
(2,860 |
) |
|
Non-cash interest on convertible loan notes |
|
|
484 |
|
|
|
— |
|
|
|
— |
|
|
|
484 |
|
|
|
— |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Accounts receivable |
|
|
(636 |
) |
|
|
529 |
|
|
|
(106 |
) |
|
|
(107 |
) |
|
|
2,137 |
|
|
Other receivables |
|
|
1,122 |
|
|
|
(1,646 |
) |
|
|
(2,644 |
) |
|
|
(524 |
) |
|
|
(5,013 |
) |
|
Prepaid expenses and other current assets |
|
|
490 |
|
|
|
53 |
|
|
|
(63 |
) |
|
|
543 |
|
|
|
(5,769 |
) |
|
Other non-current assets |
|
|
(557 |
) |
|
|
49 |
|
|
|
(236 |
) |
|
|
(508 |
) |
|
|
(1,733 |
) |
|
Trade payables |
|
|
4,542 |
|
|
|
(2,805 |
) |
|
|
(2,102 |
) |
|
|
1,737 |
|
|
|
(130 |
) |
|
Accrued expenses |
|
|
3,564 |
|
|
|
2,223 |
|
|
|
(441 |
) |
|
|
5,787 |
|
|
|
402 |
|
|
Other current and long-term liabilities |
|
|
359 |
|
|
|
(175 |
) |
|
|
(206 |
) |
|
|
184 |
|
|
|
1,614 |
|
|
Net cash used in operating activities |
|
|
(41,179 |
) |
|
|
(38,793 |
) |
|
|
(29,558 |
) |
|
|
(79,972 |
) |
|
|
(54,457 |
) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Purchase of property and equipment |
|
|
(1,935 |
) |
|
|
(1,010 |
) |
|
|
(2,109 |
) |
|
|
(2,945 |
) |
|
|
(2,822 |
) |
|
Purchase of marketable securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Proceeds from sale and maturities of marketable securities |
|
|
16,996 |
|
|
|
19,903 |
|
|
|
— |
|
|
|
36,899 |
|
|
|
— |
|
|
Purchase of asset acquisition |
|
|
— |
|
|
|
— |
|
|
|
(500 |
) |
|
|
— |
|
|
|
(500 |
) |
|
Net cash provided by (used in) investing activities |
|
|
15,061 |
|
|
|
18,893 |
|
|
|
(2,609 |
) |
|
|
33,954 |
|
|
|
(3,322 |
) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Proceeds from convertible loan notes |
|
|
80,685 |
|
|
|
— |
|
|
|
— |
|
|
|
80,685 |
|
|
|
76,723 |
|
|
Principal payments on long-term debt |
|
|
(21,316 |
) |
|
|
(4,995 |
) |
|
|
— |
|
|
|
(26,311 |
) |
|
|
— |
|
|
Proceeds from exercise of options |
|
|
516 |
|
|
|
579 |
|
|
|
146 |
|
|
|
1,095 |
|
|
|
283 |
|
|
Proceeds from exercise of warrants |
|
|
— |
|
|
|
— |
|
|
|
233 |
|
|
|
— |
|
|
|
233 |
|
|
Proceeds from issuance of warrants |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
263 |
|
|
Debt issuance costs incurred |
|
|
— |
|
|
|
— |
|
|
|
(2,416 |
) |
|
|
— |
|
|
|
(3,556 |
) |
|
Transaction costs |
|
|
(6,858 |
) |
|
|
(248 |
) |
|
|
— |
|
|
|
(7,106 |
) |
|
|
— |
|
|
Withheld taxes paid on behalf of employees on net settled stock-based awards |
|
|
— |
|
|
|
(359 |
) |
|
|
— |
|
|
|
(359 |
) |
|
|
— |
|
|
Net cash (used in) provided by financing activities |
|
|
53,027 |
|
|
|
(5,023 |
) |
|
|
(2,037 |
) |
|
|
48,004 |
|
|
|
73,946 |
|
|
Net (decrease) increase in cash and cash equivalents |
|
|
26,909 |
|
|
|
(24,923 |
) |
|
|
(34,204 |
) |
|
|
1,986 |
|
|
|
16,167 |
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Beginning of period |
|
|
11,863 |
|
|
|
36,786 |
|
|
|
69,599 |
|
|
|
36,786 |
|
|
|
19,228 |
|
|
End of period |
|
$ |
38,772 |
|
|
$ |
11,863 |
|
|
$ |
35,395 |
|
|
$ |
38,772 |
|
|
$ |
35,395 |
|
Use of Non-GAAP Financial Measures
In addition to financial information presented in accordance with GAAP, this press release includes certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, including: non-GAAP SG&A, non-GAAP R&D, non-GAAP net loss, non-GAAP net loss per share, and adjusted EBITDA, each of which is a non-GAAP financial measure. The Company defines non-GAAP SG&A as GAAP SG&A other than stock-based compensation, non-capitalized transaction costs and forgiveness of PPP loan, and non-GAAP R&D as GAAP R&D other than stock-based compensation.
Contacts
Media
Debra Raine
Rainemakers
Telephone: +1 415-349-7432
Email: rockley-pr@rainemakers.com
Investors
Gwyn Lauber
Rockley Photonics Holdings Limited
Telephone: +1 626-995-0001
Email: investors@rockleyphotonics.com
